Guest
“ The pharmaceutical industry is one of the key sectors of the EAEU economy in terms of ensuring the technological independence of its member states and it is also socially important for the EAEU population. The EAEU is steadily forming the common market of medicines, improving its regulatory mechanisms, increasing the production rate of own original and generic medicines and creating new high tech production facilities. As a result, the intertrade of pharmaceutical products within the EAEU has increased by more than 50 percent over the past 7 years. In the context of dynamic development, the EAEU pharmaceutical sector requires continued focus and flexible fine tuning by national and Eurasian regulators, with consideration to fast changing macroeconomic factors, new scientific achievements, market players’ strategies and the peculiarities of consumer behaviour. This approach will allow to fully actualize the function of this sector as a guarantor of constant growth in the quality of life of the EAEU member states citizens. The discussion will be based on the results of the EAEU pharmaceutical market survey conducted by EEC Department of Anti-monopoly regulation. Matters for discussion: shaping the EAEU common market of medicines: where we are now, what are the challenges and perspectives for further development; the role of anti-monopoly bodies in the development of competition in pharmaceutical markets; adjustment of medicines prices: best national practices, do we need to align the approaches within the EAEU; the barriers in pharmaceutical markets: what should be adjusted to make the sector develop progressively; which measures can allow to grow in-house manufacture of original and generic medicines in the EAEU and fully provide the Union citizens with affordable quality medicines.“
